While monoclonal antibody (mAb)-based therapies are promising for the treatment of Ebolavirus infection, their production is labour intensive and immunity is short-lived. Adeno-associated virus (AAV)-mediated mAb gene transfer provides the host with a genetic blueprint to manufacture mAbs in vivo, leading to the steady release of antibody over many months. The authors found that AAV-mediated expression of non-neutralising mAb 5D2 or 7C9 confers 100% protection against mouse-adapted Ebolavirus infection, while neutralising mAb 2G4 was 83% protective. In particular, a 2-component cocktail, AAV-2G4/AAV-5D2, completely protected mice when given 7 days prior to challenge and was partially protective following a 3-day lead time. These therapies were also found to provide sustained protection from challenge 5 months after AAV administration. Therefore AAV-mAb may be a viable alternative strategy for vaccination against emerging infectious diseases.
Read more here